Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

ome cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting on our be
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 With bed bugs' ... said that although bed bugs need to be eliminated, one ... not compromise a person's health. And so to help bed ... to get rid of bed bugs without using ... bed bug spray it called Bed Bug Bully. , According ...
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics ... Frederick W. Driscoll to its management team ... 30 years of financial management experience with biotechnology and ... Mr. Driscoll was chief financial officer for Novavax (NASDAQ: ... that secured more than $250 million through a combination ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Researchers from the ... the connection between lower back pain, and the acne causing ... in the system the bacteria seek out oxygen deprived location ... in the spinal column, P.acnes has the ability to live ... , Fernando Perez, a spokesman for “ The best acne ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2
... 20 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... as Senior Vice President and Chief Medical Officer. ... development and registration of cancer,therapeutics and has had ... and clinical pharmacologist, most notably at Novartis. Dr. ...
... are making a considerable impact on many aspects ... Reaching for the human frontier, robotics is also ... emerging domains. Interacting, exploring, and working with humans, ... peoples lives. The prospect of practical robots among ...
... 19 Mass spectrometry, driven by,a broad range of ... an increasing number of applications in the clinic, according,to ... Engineering and Biotechnology,News (GEN) ( http://www.genengnews.com ). Mass spec ... to a growing focus on screening patients through,the identification ...
Cached Biology Technology:Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 2Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 3Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 4Robots moving closer to humans 2Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery 2
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... popularly known as the lungs of the planet, inhales carbon ... the air to grow parts that eventually fall to the ... plentiful rainfall. , Until recently people believed much of ... ended up deep in the ocean. University of Washington research ... carbon dioxide though left open the question of how ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... TGen Drug Development (TD2) and the Institut ... will enable both to maximize their worldwide contributions ... The partnership between TD2, a Scottsdale subsidiary of ... Marseille, France-based IPC,s comprehensive cancer center will enable ...
... University Medical Center in New York have confirmed that ... not a descendant of healthy humans dwarfed by disease. ... specimen, researchers determined the "hobbit" to be a distinct species ... Details of the study appear in the December issue of ...
... a step toward using human saliva to tell whether those ... are normal or red flags for disease, scientists are describing ... age. The discovery could lead to a simple, noninvasive test ... they suggest in a report in ACS, Journal of ...
Cached Biology News:TGen Drug Development establishes European footprint 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
Glutamate Receptor 5/1a...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Gentamicin sulfate, 5g...
Biology Products: